{"issuance_frequency":"","notes_translated":{"fr":"Le Relevé des maladies transmissibles au Canada est une publication bilingue et libre d'accès revue par un comité de lecture portant sur la prévention et le contrôle des maladies infectieuses nouvelles et tenaces.\r\n","en":"The Canada Communicable Disease Report is a bilingual, open-access, peer-reviewed journal on the prevention and control of emerging and persistent infectious diseases.\r\n"},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"unknown","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","metadata_created":"2020-11-04T20:31:11.574668","subject":["health_and_safety"],"date_modified":"2020-10-22 00:00:00","pspc_identification_number":"","metadata_modified":"2020-11-04T20:31:11.574674","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2020-11-04","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["liste de contrôle","COVID-19","Ebola","maladie infectieuse émergente","gestion des urgences","agents pathogènes à haute conséquence","maladie infectieuse","intervention des laboratoires","préparation aux épidémies","interventions contre les épidémies","laboratoire de santé publique","SRAS","SRAS-CoV-2","Zika","COVID-19","Canada","dépistage aux points de service","Comité consultatif national de l’immunisation","CCNI","mammifères","culture cellulaire","MDCK","vaccin antigrippal","spectrométrie de masse MALDI-TOF","pathogènes bactériens","diagnostics de laboratoire de microbiologie clinique","cote de sécurité élevée","immunisation","méningococcie","méningococcie invasive","sérotype W","COVID-19","Canada","mortalité","épidémiologie","taux de létalité","myélite flasque aiguë","paralysie flasque aiguë","entérovirus","maladie infectieuse","surveillance","maladie de Lyme","surveillance sentinelle","tique Ixodes","Borrelia","Canadian Lyme Disease Research Network (CLyDRN)","fièvre récurrente à tiques","Borrelia hermsii","Ornithodoros","réaction de Jarisch-Herxheimer","surveillance de la maladie","immunisation","programmes scolaires","santé publique","douleur","peur","guide de pratiques cliniques","hésitation vaccinale"],"en":["checklist","COVID-19","Ebola","emerging infectious disease","emergency management","high consequence pathogens","infectious disease","laboratory response","outbreak preparedness","outbreak response","public health laboratory","SARS","SARS-CoV-2","Zika","COVID-19","Canada","point-of-care testing","National Advisory Committee on Immunization","NACI","mammalian","cell culture","MDCK","influenza vaccine","MALDI-TOF mass spectrometry","bacterial pathogens","clinical microbiology laboratory diagnostics","security-sensitive","immunization","meningococcal disease","IMD","serotype W","COVID-19","Canada","mortality","epidemiology","case fatality rate","acute flaccid myelitis","acute flaccid paralysis","enterovirus","infectious disease","surveillance","Lyme disease","sentinel surveillance","Ixodes tick","Borrelia","Canadian Lyme Disease Research Network (CLyDRN)","tick-borne relapsing fever","Borrelia hermsii","Ornithodoros","Jarisch-Herxheimer reaction","disease surveillance","immunization","school programs","public health","pain","fear","clinical practice guideline","vaccine hesitancy"]},"relationships_as_object":[],"creator_user_id":"4cfa9a9c-1d95-40eb-86f9-bc0c8ec45d1f","title_translated":{"fr":"RMTC : Volume 46–10- octobre 2020 : Biosécurité en Laboratoire","en":"CCDR: Volume 46-10-October 2020: Laboratory Biosafety"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"e0274eea-a547-4812-bec9-fbf13690f66b","related_relationship":"","name_translated":{"fr":"RMTC : Volume 46–10- octobre 2020 : Biosécurité en Laboratoire","en":"CCDR: Volume 46-10-October 2020: Laboratory Biosafety"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"CCDR: Volume 46-10-October 2020: Laboratory Biosafety","language":["en"],"created":"2020-11-04T20:31:11.737795","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr.html","last_modified":null,"position":0,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"c3fff259-c6c9-4f19-b154-853bd2f84c1d","related_relationship":"","name_translated":{"fr":"RMTC : Volume 46–10- octobre 2020 : Biosécurité en Laboratoire","en":"CCDR: Volume 46-10-October 2020: Laboratory Biosafety"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"CCDR: Volume 46-10-October 2020: Laboratory Biosafety","language":["fr"],"created":"2020-11-04T20:31:11.737804","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc.html","last_modified":null,"position":1,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"ce9b3030-c6a6-41e1-853f-4bbddd6563d1","related_relationship":"","name_translated":{"fr":"RMTC : Volume 46–10- octobre 2020 : Biosécurité en Laboratoire","en":"CCDR: Volume 46-10-October 2020: Laboratory Biosafety"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"CCDR: Volume 46-10-October 2020: Laboratory Biosafety","language":["en"],"created":"2020-11-04T20:31:11.737807","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-oct-1-2020/ccdrv46i10-eng.pdf","last_modified":null,"position":2,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"803008c0-526d-47d3-b228-9ab4b0d28bc4","related_relationship":"","name_translated":{"fr":"RMTC : Volume 46–10- octobre 2020 : Biosécurité en Laboratoire","en":"CCDR: Volume 46-10-October 2020: Laboratory Biosafety"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"CCDR: Volume 46-10-October 2020: Laboratory Biosafety","language":["fr"],"created":"2020-11-04T20:31:11.737809","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-oct-1-2020/ccdrv46i10f-fra.pdf","last_modified":null,"position":3,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"c126566b-565a-4bbd-b9f5-173b4e15d0a4","related_relationship":"","name_translated":{"fr":"Liste de contrôle pour laboratoires d’intervention contre les éclosions de maladie infectieuse – Considérations relatives aux mesures de préparation et interventions face aux menaces émergentes","en":"Laboratory response checklist for infectious disease outbreaks—preparedness and response considerations for emerging threats"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Laboratory response checklist for infectious disease outbreaks—preparedness and response considerations for emerging threats","language":["en"],"created":"2020-11-04T20:31:11.737811","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-october-1-2020/laboratory-checklist-infectious-disease-outbreaks.html","last_modified":null,"position":4,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"1dd1ec02-1564-48a7-80e3-778fc9b8d4c3","related_relationship":"","name_translated":{"fr":"Liste de contrôle pour laboratoires d’intervention contre les éclosions de maladie infectieuse – Considérations relatives aux mesures de préparation et interventions face aux menaces émergentes","en":"Laboratory response checklist for infectious disease outbreaks—preparedness and response considerations for emerging threats"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Laboratory response checklist for infectious disease outbreaks—preparedness and response considerations for emerging threats","language":["fr"],"created":"2020-11-04T20:31:11.737813","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-10-1-octobre-2020/liste-controle-laboratoire-contre-eclosions-maladies-infectieuses.html","last_modified":null,"position":5,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"d25a7d09-736e-4269-8e1b-082b79fadc74","related_relationship":"","name_translated":{"fr":"Liste de contrôle pour laboratoires d’intervention contre les éclosions de maladie infectieuse – Considérations relatives aux mesures de préparation et interventions face aux menaces émergentes","en":"Laboratory response checklist for infectious disease outbreaks—preparedness and response considerations for emerging threats"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Laboratory response checklist for infectious disease outbreaks—preparedness and response considerations for emerging threats","language":["en"],"created":"2020-11-04T20:31:11.737815","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-oct-1-2020/ccdrv46i10a01-eng.pdf","last_modified":null,"position":6,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"a97e7dcc-c176-4afc-aa4e-3708e49c0ae8","related_relationship":"","name_translated":{"fr":"Liste de contrôle pour laboratoires d’intervention contre les éclosions de maladie infectieuse – Considérations relatives aux mesures de préparation et interventions face aux menaces émergentes","en":"Laboratory response checklist for infectious disease outbreaks—preparedness and response considerations for emerging threats"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Laboratory response checklist for infectious disease outbreaks—preparedness and response considerations for emerging threats","language":["fr"],"created":"2020-11-04T20:31:11.737817","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-oct-1-2020/ccdrv46i10a01f-fra.pdf","last_modified":null,"position":7,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"e2a3c169-35e1-4242-be21-14d297acc86a","related_relationship":"","name_translated":{"fr":"Réseau des laboratoires de santé publique du Canada : soutien prioritaire pour les régions éloignées et isolées du Nord du Canada","en":"Canadian Public Health Laboratory Network: Prioritized support for northern, remote and isolated communities in Canada"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Canadian Public Health Laboratory Network: Prioritized support for northern, remote and isolated communities in Canada","language":["en"],"created":"2020-11-04T20:31:11.737819","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-october-1-2020/canadian-public-health-laboratory-network-supporting-northern-remote-communitites.html","last_modified":null,"position":8,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"7815e992-ef45-4f80-a964-f9d0f7ec55b6","related_relationship":"","name_translated":{"fr":"Réseau des laboratoires de santé publique du Canada : soutien prioritaire pour les régions éloignées et isolées du Nord du Canada","en":"Canadian Public Health Laboratory Network: Prioritized support for northern, remote and isolated communities in Canada"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Canadian Public Health Laboratory Network: Prioritized support for northern, remote and isolated communities in Canada","language":["fr"],"created":"2020-11-04T20:31:11.737822","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-10-1-octobre-2020/reseau-laboratoires-sante-publique-canada-soutenant-communautes-isolees-nord.html","last_modified":null,"position":9,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"70779a41-c88d-4c6e-9d07-9447271f29ea","related_relationship":"","name_translated":{"fr":"Réseau des laboratoires de santé publique du Canada : soutien prioritaire pour les régions éloignées et isolées du Nord du Canada","en":"Canadian Public Health Laboratory Network: Prioritized support for northern, remote and isolated communities in Canada"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Canadian Public Health Laboratory Network: Prioritized support for northern, remote and isolated communities in Canada","language":["en"],"created":"2020-11-04T20:31:11.737824","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-oct-1-2020/ccdrv46i10a02-eng.pdf","last_modified":null,"position":10,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"953f279e-17ed-4b26-bbf6-626c138c4de3","related_relationship":"","name_translated":{"fr":"Réseau des laboratoires de santé publique du Canada : soutien prioritaire pour les régions éloignées et isolées du Nord du Canada","en":"Canadian Public Health Laboratory Network: Prioritized support for northern, remote and isolated communities in Canada"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Canadian Public Health Laboratory Network: Prioritized support for northern, remote and isolated communities in Canada","language":["fr"],"created":"2020-11-04T20:31:11.737826","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-oct-1-2020/ccdrv46i10a02f-fra.pdf","last_modified":null,"position":11,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"f739b01e-f7a9-40eb-a124-c66d3241beaa","related_relationship":"","name_translated":{"fr":"Résumé de la déclaration supplémentaire du CCNI sur les vaccins antigrippaux issus de cultures cellulaires de mammifères","en":"Summary of the NACI Supplemental Statement on Mammalian Cell Culture-Based Influenza Vaccines"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Summary of the NACI Supplemental Statement on Mammalian Cell Culture-Based Influenza Vaccines","language":["en"],"created":"2020-11-04T20:31:11.737828","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-october-1-2020/national-advisory-committee-immunization-supplemental-statement.html","last_modified":null,"position":12,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"6cb5530c-7a40-4f24-95a3-817710858c74","related_relationship":"","name_translated":{"fr":"Résumé de la déclaration supplémentaire du CCNI sur les vaccins antigrippaux issus de cultures cellulaires de mammifères","en":"Summary of the NACI Supplemental Statement on Mammalian Cell Culture-Based Influenza Vaccines"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Summary of the NACI Supplemental Statement on Mammalian Cell Culture-Based Influenza Vaccines","language":["fr"],"created":"2020-11-04T20:31:11.737830","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-10-1-octobre-2020/declaration-supplementaire-comite-consultatif-national-immunisation.html","last_modified":null,"position":13,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"af694179-6869-43c1-b222-f89f21bc8a21","related_relationship":"","name_translated":{"fr":"Résumé de la déclaration supplémentaire du CCNI sur les vaccins antigrippaux issus de cultures cellulaires de mammifères","en":"Summary of the NACI Supplemental Statement on Mammalian Cell Culture-Based Influenza Vaccines"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Summary of the NACI Supplemental Statement on Mammalian Cell Culture-Based Influenza Vaccines","language":["en"],"created":"2020-11-04T20:31:11.737832","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-oct-1-2020/ccdrv46i10a03-eng.pdf","last_modified":null,"position":14,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"af01e7a6-57d3-4d04-b5f9-210b9f13567d","related_relationship":"","name_translated":{"fr":"Résumé de la déclaration supplémentaire du CCNI sur les vaccins antigrippaux issus de cultures cellulaires de mammifères","en":"Summary of the NACI Supplemental Statement on Mammalian Cell Culture-Based Influenza Vaccines"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Summary of the NACI Supplemental Statement on Mammalian Cell Culture-Based Influenza Vaccines","language":["fr"],"created":"2020-11-04T20:31:11.737834","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-oct-1-2020/ccdrv46i10a03f-fra.pdf","last_modified":null,"position":15,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"0c662a24-e52f-4aaa-b121-d244303559ff","related_relationship":"","name_translated":{"fr":"Identification des bactéries à cote de sécurité élevée, basée sur la spectrométrie de masse à temps de vol après désorption/ionisation laser assistée par matrice : considérations pour les utilisateurs canadiens de Bruker","en":"Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry-based identification of security-sensitive bacteria: Considerations for Canadian Bruker users"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry-based identification of security-sensitive bacteria: Considerations for Canadian Bruker users","language":["en"],"created":"2020-11-04T20:31:11.737836","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-october-1-2020/matrix-assisted-laser-desorption-ionization-time-identififcation-security-sensitive-bacteria.html","last_modified":null,"position":16,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"585c12e3-e775-4f39-8365-5dc4e9a83613","related_relationship":"","name_translated":{"fr":"Identification des bactéries à cote de sécurité élevée, basée sur la spectrométrie de masse à temps de vol après désorption/ionisation laser assistée par matrice : considérations pour les utilisateurs canadiens de Bruker","en":"Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry-based identification of security-sensitive bacteria: Considerations for Canadian Bruker users"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry-based identification of security-sensitive bacteria: Considerations for Canadian Bruker users","language":["fr"],"created":"2020-11-04T20:31:11.737838","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-10-1-octobre-2020/identification-bacteries-securite-elevee-desorption-ionisation-laser-assistee-matrice-mesure-temps-vol.html","last_modified":null,"position":17,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"1f9a6bbb-ddd6-4ce6-be2f-345a5c5f2da1","related_relationship":"","name_translated":{"fr":"Identification des bactéries à cote de sécurité élevée, basée sur la spectrométrie de masse à temps de vol après désorption/ionisation laser assistée par matrice : considérations pour les utilisateurs canadiens de Bruker","en":"Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry-based identification of security-sensitive bacteria: Considerations for Canadian Bruker users"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry-based identification of security-sensitive bacteria: Considerations for Canadian Bruker users","language":["en"],"created":"2020-11-04T20:31:11.737839","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-oct-1-2020/ccdrv46i10a04-eng.pdf","last_modified":null,"position":18,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"8f8015ac-29ad-45dc-a295-0f724d7fc697","related_relationship":"","name_translated":{"fr":"Identification des bactéries à cote de sécurité élevée, basée sur la spectrométrie de masse à temps de vol après désorption/ionisation laser assistée par matrice : considérations pour les utilisateurs canadiens de Bruker","en":"Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry-based identification of security-sensitive bacteria: Considerations for Canadian Bruker users"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry-based identification of security-sensitive bacteria: Considerations for Canadian Bruker users","language":["fr"],"created":"2020-11-04T20:31:11.737842","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-oct-1-2020/ccdrv46i10a04f-fra.pdf","last_modified":null,"position":19,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"ab5a96c3-3543-492e-a454-f0c489dfcf2e","related_relationship":"","name_translated":{"fr":"Étude du Réseau collaboratif des chercheurs pédiatriques sur les infections au Canada (PICNIC) sur le paysage actuel des méningococcies invasives chez les enfants","en":"Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of the current landscape of invasive meningococcal disease in children"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of the current landscape of invasive meningococcal disease in children","language":["en"],"created":"2020-11-04T20:31:11.737843","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-october-1-2020/study-invasive-meningococcal-disease-children.html","last_modified":null,"position":20,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"c1eaf2b0-27f4-4fdc-b879-9521659593ef","related_relationship":"","name_translated":{"fr":"Étude du Réseau collaboratif des chercheurs pédiatriques sur les infections au Canada (PICNIC) sur le paysage actuel des méningococcies invasives chez les enfants","en":"Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of the current landscape of invasive meningococcal disease in children"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of the current landscape of invasive meningococcal disease in children","language":["fr"],"created":"2020-11-04T20:31:11.737845","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-10-1-octobre-2020/etude-meningococcies-invasives-enfants.html","last_modified":null,"position":21,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"4b69f37e-a1d7-4da4-970b-7bb4e50a27a4","related_relationship":"","name_translated":{"fr":"Étude du Réseau collaboratif des chercheurs pédiatriques sur les infections au Canada (PICNIC) sur le paysage actuel des méningococcies invasives chez les enfants","en":"Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of the current landscape of invasive meningococcal disease in children"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of the current landscape of invasive meningococcal disease in children","language":["en"],"created":"2020-11-04T20:31:11.737847","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-oct-1-2020/ccdrv46i10a05-eng.pdf","last_modified":null,"position":22,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"0f11e360-f70c-41e4-9cc2-f1fb71afffab","related_relationship":"","name_translated":{"fr":"Étude du Réseau collaboratif des chercheurs pédiatriques sur les infections au Canada (PICNIC) sur le paysage actuel des méningococcies invasives chez les enfants","en":"Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of the current landscape of invasive meningococcal disease in children"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of the current landscape of invasive meningococcal disease in children","language":["fr"],"created":"2020-11-04T20:31:11.737850","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-oct-1-2020/ccdrv46i10a05f-fra.pdf","last_modified":null,"position":23,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"86a6171e-a864-4392-831d-de8b81e6c865","related_relationship":"","name_translated":{"fr":"Épidémiologie descriptive des cas décédés de COVID-19 signalés lors de la première vague de l’épidémie au Canada, du 15 janvier au 9 juillet 2020 ","en":"Descriptive epidemiology of deceased cases of COVID-19 reported during the initial wave of the epidemic in Canada, January 15 to July 9, 2020"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Descriptive epidemiology of deceased cases of COVID-19 reported during the initial wave of the epidemic in Canada, January 15 to July 9, 2020","language":["en"],"created":"2020-11-04T20:31:11.737852","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-october-1-2020/epidemiology-deceased-cases-covid-19.html","last_modified":null,"position":24,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"aac3ff08-fbad-48e5-8b6e-59a793430bee","related_relationship":"","name_translated":{"fr":"Épidémiologie descriptive des cas décédés de COVID-19 signalés lors de la première vague de l’épidémie au Canada, du 15 janvier au 9 juillet 2020","en":"Descriptive epidemiology of deceased cases of COVID-19 reported during the initial wave of the epidemic in Canada, January 15 to July 9, 2020"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Descriptive epidemiology of deceased cases of COVID-19 reported during the initial wave of the epidemic in Canada, January 15 to July 9, 2020","language":["fr"],"created":"2020-11-04T20:31:11.737854","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-10-1-octobre-2020/epidemiologie-covid-19-decedes.html","last_modified":null,"position":25,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"2443540a-bc80-4be4-a155-c9de917f2155","related_relationship":"","name_translated":{"fr":"Épidémiologie descriptive des cas décédés de COVID-19 signalés lors de la première vague de l’épidémie au Canada, du 15 janvier au 9 juillet 2020","en":"Descriptive epidemiology of deceased cases of COVID-19 reported during the initial wave of the epidemic in Canada, January 15 to July 9, 2020"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Descriptive epidemiology of deceased cases of COVID-19 reported during the initial wave of the epidemic in Canada, January 15 to July 9, 2020","language":["en"],"created":"2020-11-04T20:31:11.737855","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-oct-1-2020/ccdrv46i10a06-eng.pdf","last_modified":null,"position":26,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"559fcaaa-e592-43b0-9911-ec69de8edddc","related_relationship":"","name_translated":{"fr":"Épidémiologie descriptive des cas décédés de COVID-19 signalés lors de la première vague de l’épidémie au Canada, du 15 janvier au 9 juillet 2020","en":"Descriptive epidemiology of deceased cases of COVID-19 reported during the initial wave of the epidemic in Canada, January 15 to July 9, 2020"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Descriptive epidemiology of deceased cases of COVID-19 reported during the initial wave of the epidemic in Canada, January 15 to July 9, 2020","language":["fr"],"created":"2020-11-04T20:31:11.737858","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-oct-1-2020/ccdrv46i10a06f-fra.pdf","last_modified":null,"position":27,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"824fb910-888f-4d1b-bb88-44b1facbf12d","related_relationship":"","name_translated":{"fr":"Myélite flasque aiguë au Canada, 2018 à 2019","en":"Acute flaccid myelitis in Canada, 2018 to 2019"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Acute flaccid myelitis in Canada, 2018 to 2019","language":["en"],"created":"2020-11-04T20:31:11.737859","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-october-1-2020/acute-flaccid-myelitis.html","last_modified":null,"position":28,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"77a2ef24-eb6c-4731-b2b7-825c05a75bcf","related_relationship":"","name_translated":{"fr":"Myélite flasque aiguë au Canada, 2018 à 2019","en":"Acute flaccid myelitis in Canada, 2018 to 2019"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Acute flaccid myelitis in Canada, 2018 to 2019","language":["fr"],"created":"2020-11-04T20:31:11.737861","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-10-1-octobre-2020/myelite-flasque-aigue.html","last_modified":null,"position":29,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"3b8a4c09-054f-4707-beb2-c8283262ba7e","related_relationship":"","name_translated":{"fr":"Myélite flasque aiguë au Canada, 2018 à 2019","en":"Acute flaccid myelitis in Canada, 2018 to 2019"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Acute flaccid myelitis in Canada, 2018 to 2019","language":["en"],"created":"2020-11-04T20:31:11.737864","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-oct-1-2020/ccdrv46i10a07-eng.pdf","last_modified":null,"position":30,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"2797a4f4-28ca-454e-8186-aab07f22b938","related_relationship":"","name_translated":{"fr":"Myélite flasque aiguë au Canada, 2018 à 2019","en":"Acute flaccid myelitis in Canada, 2018 to 2019"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Acute flaccid myelitis in Canada, 2018 to 2019","language":["fr"],"created":"2020-11-04T20:31:11.737865","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-oct-1-2020/ccdrv46i10a07f-fra.pdf","last_modified":null,"position":31,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"8d0e0a47-f9fd-413f-b84f-337a560060b8","related_relationship":"","name_translated":{"fr":"Surveillance sentinelle du risque de la maladie de Lyme au Canada, 2019 : résultats de la première année du Réseau sentinelle canadien de surveillance de la maladie de Lyme (ReSCaL)","en":"Sentinel surveillance of Lyme disease risk in Canada, 2019: Results from the first year of the Canadian Lyme Sentinel Network (CaLSeN)"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Sentinel surveillance of Lyme disease risk in Canada, 2019: Results from the first year of the Canadian Lyme Sentinel Network (CaLSeN)","language":["en"],"created":"2020-11-04T20:31:11.737867","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-october-1-2020/lyme-sentinel-surveillance-report.html","last_modified":null,"position":32,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"33aa88cb-1e24-449d-9a5b-a0ec209cb534","related_relationship":"","name_translated":{"fr":"Surveillance sentinelle du risque de la maladie de Lyme au Canada, 2019 : résultats de la première année du Réseau sentinelle canadien de surveillance de la maladie de Lyme (ReSCaL)","en":"Sentinel surveillance of Lyme disease risk in Canada, 2019: Results from the first year of the Canadian Lyme Sentinel Network (CaLSeN)"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Sentinel surveillance of Lyme disease risk in Canada, 2019: Results from the first year of the Canadian Lyme Sentinel Network (CaLSeN)","language":["fr"],"created":"2020-11-04T20:31:11.737869","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-10-1-octobre-2020/rapport-surveillance-sentinelle-maladie-lyme.html","last_modified":null,"position":33,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"34203f5f-74b9-4135-92ab-6d5d2249f19d","related_relationship":"","name_translated":{"fr":"Surveillance sentinelle du risque de la maladie de Lyme au Canada, 2019 : résultats de la première année du Réseau sentinelle canadien de surveillance de la maladie de Lyme (ReSCaL)","en":"Sentinel surveillance of Lyme disease risk in Canada, 2019: Results from the first year of the Canadian Lyme Sentinel Network (CaLSeN)"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Sentinel surveillance of Lyme disease risk in Canada, 2019: Results from the first year of the Canadian Lyme Sentinel Network (CaLSeN)","language":["en"],"created":"2020-11-04T20:31:11.737871","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-oct-1-2020/ccdrv46i10a08-eng.pdf","last_modified":null,"position":34,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"a040f1bf-9a9e-4741-82aa-5802d696f299","related_relationship":"","name_translated":{"fr":"Surveillance sentinelle du risque de la maladie de Lyme au Canada, 2019 : résultats de la première année du Réseau sentinelle canadien de surveillance de la maladie de Lyme (ReSCaL)","en":"Sentinel surveillance of Lyme disease risk in Canada, 2019: Results from the first year of the Canadian Lyme Sentinel Network (CaLSeN)"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Sentinel surveillance of Lyme disease risk in Canada, 2019: Results from the first year of the Canadian Lyme Sentinel Network (CaLSeN)","language":["fr"],"created":"2020-11-04T20:31:11.737873","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-oct-1-2020/ccdrv46i10a08f-fra.pdf","last_modified":null,"position":35,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"0bc9e663-9e89-4b85-855e-24bacddde613","related_relationship":"","name_translated":{"fr":"Un cas de fièvre récurrente à tiques pendant la grossesse","en":"A case of tick-borne relapsing fever in pregnancy"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"A case of tick-borne relapsing fever in pregnancy","language":["en"],"created":"2020-11-04T20:31:11.737875","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-october-1-2020/tick-borne-fever-pregnancy.html","last_modified":null,"position":36,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"89df9a21-8b6f-4ea9-a8bf-bd122fa28e3d","related_relationship":"","name_translated":{"fr":"Un cas de fièvre récurrente à tiques pendant la grossesse","en":"A case of tick-borne relapsing fever in pregnancy"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"A case of tick-borne relapsing fever in pregnancy","language":["fr"],"created":"2020-11-04T20:31:11.737877","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-10-1-octobre-2020/fievre-tiques-pendant-grossesse.html","last_modified":null,"position":37,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"f834ce3b-1546-4150-a2ef-505d6982571c","related_relationship":"","name_translated":{"fr":"Un cas de fièvre récurrente à tiques pendant la grossesse","en":"A case of tick-borne relapsing fever in pregnancy"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"A case of tick-borne relapsing fever in pregnancy","language":["en"],"created":"2020-11-04T20:31:11.737879","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-oct-1-2020/ccdrv46i10a09-eng.pdf","last_modified":null,"position":38,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"1d0e4304-640c-4eb0-9449-fc129e5bce96","related_relationship":"","name_translated":{"fr":"Un cas de fièvre récurrente à tiques pendant la grossesse","en":"A case of tick-borne relapsing fever in pregnancy"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"A case of tick-borne relapsing fever in pregnancy","language":["fr"],"created":"2020-11-04T20:31:11.737881","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-oct-1-2020/ccdrv46i10a09f-fra.pdf","last_modified":null,"position":39,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"b3926f70-fd3d-4644-939d-5dd5fe1b5eb5","related_relationship":"","name_translated":{"fr":"Infographie : La syphilis infectieuse au Canada, 2019","en":"Infographic:  Infectious Syphilis in Canada, 2019"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Infographic:  Infectious Syphilis in Canada, 2019","language":["en"],"created":"2020-11-04T20:31:11.737883","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-october-1-2020/infectious-syphilis-2019.html","last_modified":null,"position":40,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"5d73bd6e-19b6-49ea-bc53-53cd803c46c7","related_relationship":"","name_translated":{"fr":"Infographie : La syphilis infectieuse au Canada, 2019","en":"Infographic:  Infectious Syphilis in Canada, 2019"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Infographic:  Infectious Syphilis in Canada, 2019","language":["fr"],"created":"2020-11-04T20:31:11.737885","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-10-1-octobre-2020/syphilis-infectieuse-2019.html","last_modified":null,"position":41,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"30260bf3-6aae-4fbe-8019-89e792791c34","related_relationship":"","name_translated":{"fr":"Infographie : La syphilis infectieuse au Canada, 2019","en":"Infographic:  Infectious Syphilis in Canada, 2019"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Infographic:  Infectious Syphilis in Canada, 2019","language":["en"],"created":"2020-11-04T20:31:11.737887","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-oct-1-2020/ccdrv46i10a09a-eng.pdf","last_modified":null,"position":42,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"c7ea9a1c-af1e-424c-8d13-2fca564889f7","related_relationship":"","name_translated":{"fr":"Infographie : La syphilis infectieuse au Canada, 2019","en":"Infographic:  Infectious Syphilis in Canada, 2019"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Infographic:  Infectious Syphilis in Canada, 2019","language":["fr"],"created":"2020-11-04T20:31:11.737889","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-oct-1-2020/ccdrv46i10a09af-fra.pdf","last_modified":null,"position":43,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"f2ca149f-1f62-4110-8eb3-a942949add84","related_relationship":"","name_translated":{"fr":"Infographie : Syphilis chez les femmes et syphilis congénitale au Canada, 2019","en":"Infographic: Syphilis in Women and Congenital Syphilis in Canada, 2019"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Infographic: Syphilis in Women and Congenital Syphilis in Canada, 2019","language":["en"],"created":"2020-11-04T20:31:11.737891","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-october-1-2020/women-syphilis-2015-2019.html","last_modified":null,"position":44,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"5e31c915-2c88-4188-91ae-92cb8b21e07b","related_relationship":"","name_translated":{"fr":"Infographie : Syphilis chez les femmes et syphilis congénitale au Canada, 2019","en":"Infographic: Syphilis in Women and Congenital Syphilis in Canada, 2019"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Infographic: Syphilis in Women and Congenital Syphilis in Canada, 2019","language":["fr"],"created":"2020-11-04T20:31:11.737893","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-10-1-octobre-2020/syphilis-congenitale-femmes-canadiennes-2015-2019.html","last_modified":null,"position":45,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"1adafecc-1cb5-46c8-9bc7-21a0562a4270","related_relationship":"","name_translated":{"fr":"Infographie : Syphilis chez les femmes et syphilis congénitale au Canada, 2019","en":"Infographic: Syphilis in Women and Congenital Syphilis in Canada, 2019"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Infographic: Syphilis in Women and Congenital Syphilis in Canada, 2019","language":["en"],"created":"2020-11-04T20:31:11.737895","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-oct-1-2020/ccdrv46i10a09b-eng.pdf","last_modified":null,"position":46,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"de4076a7-2ae1-4e90-bae7-4ddc5b371113","related_relationship":"","name_translated":{"fr":"Infographie : Syphilis chez les femmes et syphilis congénitale au Canada, 2019","en":"Infographic: Syphilis in Women and Congenital Syphilis in Canada, 2019"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Infographic: Syphilis in Women and Congenital Syphilis in Canada, 2019","language":["fr"],"created":"2020-11-04T20:31:11.737897","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-oct-1-2020/ccdrv46i10a09bf-fra.pdf","last_modified":null,"position":47,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"6bd4b244-1558-472a-ba06-d142a681f6ab","related_relationship":"","name_translated":{"fr":"Étalonnage des pratiques de santé publique en matière de gestion de la douleur lors des vaccinations en milieu scolaire ","en":"Benchmarking public health pain management practices during school immunizations "},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Benchmarking public health pain management practices during school immunizations ","language":["en"],"created":"2020-11-04T20:31:11.737899","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-october-1-2020/pain-management-during-school-immunization-clinics.html","last_modified":null,"position":48,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"d04fab8e-8ea4-4b3a-8b34-6f8e6d160232","related_relationship":"","name_translated":{"fr":"Étalonnage des pratiques de santé publique en matière de gestion de la douleur lors des vaccinations en milieu scolaire ","en":"Benchmarking public health pain management practices during school immunizations "},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Benchmarking public health pain management practices during school immunizations ","language":["fr"],"created":"2020-11-04T20:31:11.737901","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-10-1-octobre-2020/gestion-douleur-seances-vaccination-ecole.html","last_modified":null,"position":49,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"5b12eb41-6616-43d0-b66e-66dd668194e8","related_relationship":"","name_translated":{"fr":"Étalonnage des pratiques de santé publique en matière de gestion de la douleur lors des vaccinations en milieu scolaire ","en":"Benchmarking public health pain management practices during school immunizations "},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Benchmarking public health pain management practices during school immunizations ","language":["en"],"created":"2020-11-04T20:31:11.737903","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-oct-1-2020/ccdrv46i10a10-eng.pdf","last_modified":null,"position":50,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"9bb695c1-fb18-4523-8654-5be2a48660ee","related_relationship":"","name_translated":{"fr":"Étalonnage des pratiques de santé publique en matière de gestion de la douleur lors des vaccinations en milieu scolaire","en":"Benchmarking public health pain management practices during school immunizations"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Benchmarking public health pain management practices during school immunizations","language":["fr"],"created":"2020-11-04T20:31:11.737905","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-oct-1-2020/ccdrv46i10a10f-fra.pdf","last_modified":null,"position":51,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"6bd5e86b-3c1f-4ea5-88bb-f33cfae4aaef","related_relationship":"","name_translated":{"fr":"Facteurs qui augmentent ou réduisent le risque d’éclosion de COVID-19 en milieu de travail ","en":"What increases and decreases the risk of COVID-19 outbreaks in the workplace "},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"What increases and decreases the risk of COVID-19 outbreaks in the workplace ","language":["en"],"created":"2020-11-04T20:31:11.737907","url":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-october-1-2020/risks-covid-19-workplace.html","last_modified":null,"position":52,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"f5b11105-8c9f-4661-bdd9-120847d47686","related_relationship":"","name_translated":{"fr":"Facteurs qui augmentent ou réduisent le risque d’éclosion de COVID-19 en milieu de travail ","en":"What increases and decreases the risk of COVID-19 outbreaks in the workplace "},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"What increases and decreases the risk of COVID-19 outbreaks in the workplace ","language":["fr"],"created":"2020-11-04T20:31:11.737909","url":"https://www.canada.ca/fr/sante-publique/services/rapports-publications/releve-maladies-transmissibles-canada-rmtc/numero-mensuel/2020-46/numero-10-1-octobre-2020/risques-covid-19-travail.html","last_modified":null,"position":53,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"567713b9-e6d3-4760-b1ae-836a7597e153","related_relationship":"","name_translated":{"fr":"Facteurs qui augmentent ou réduisent le risque d’éclosion de COVID-19 en milieu de travail","en":"What increases and decreases the risk of COVID-19 outbreaks in the workplace"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"What increases and decreases the risk of COVID-19 outbreaks in the workplace","language":["en"],"created":"2020-11-04T20:31:11.737911","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-oct-1-2020/ccdrv46i10a11-eng.pdf","last_modified":null,"position":54,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"cf030f76-d22d-4ebf-9b8b-bf19338a13c3","related_relationship":"","name_translated":{"fr":"Facteurs qui augmentent ou réduisent le risque d’éclosion de COVID-19 en milieu de travail","en":"What increases and decreases the risk of COVID-19 outbreaks in the workplace"},"hash":"","description":"","format":"PDF","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"What increases and decreases the risk of COVID-19 outbreaks in the workplace","language":["fr"],"created":"2020-11-04T20:31:11.737913","url":"https://www.canada.ca/content/dam/phac-aspc/documents/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2020-46/issue-10-oct-1-2020/ccdrv46i10a11f-fra.pdf","last_modified":null,"position":55,"revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db","resource_type":"website"}],"place_of_publication":[],"num_resources":56,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Agence de la santé publique du Canada","en":"Public Health Agency of Canada"},"date_published":"2020-10-01 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:57.068700","title":"Public Health Agency of Canada | Agence de la santé publique du Canada","name":"phac-aspc","is_organization":true,"state":"active","image_url":"","revision_id":"96161da6-edc7-4d1d-99e0-baac9df7b3b9","type":"organization","id":"1C71053B-AA64-4646-956B-41631C396018","approval_status":"approved"},"name":"a8df9b73-d835-4c5a-9536-bcb0e9d446e7","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"The Canada Communicable Disease Report is a bilingual, open-access, peer-reviewed journal on the prevention and control of emerging and persistent infectious diseases.\r\n","owner_org":"1C71053B-AA64-4646-956B-41631C396018","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"CCDR: Volume 46-10-October 2020: Laboratory Biosafety","revision_id":"5e3c3901-1053-4d1c-bba4-67aa855374db"}